TABLE 4.
Gene | 2−ΔΔCT |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
C | CIP | EDA | CIP+E | LEV | TMP | FOS | AMX | AMC | NIT | CFX | ERY | |
recA | 1 | 12.5 ± 1.6 | 0.6 ± 0.2 | 4.0 ± 0.5 | 2.6 ± 0.4 | 2.7 ± 0.2 | 1.75 ± 0.7 | 0.9 ± 0.1 | 0.9 ± 0.1 | 2.5 ± 0.3 | 2.2 ± 0.1 | 1.2 ± 0.4 |
sfiA | 1 | 6 ± 1.7 | 0.4 ± 0.2 | 3.0 ± 0.3 | 3.5 ± 0.4 | 1.3 ± 0.1 | 1.3 ± 0.3 | 0.7 ± 0.2 | 0.7 ± 0.2 | 2.7 ± 0.3 | 1.9 ± 0.8 | 1.2 ± 0.3 |
C, control; CIP, ciprofloxacin (0.002 mg/liter); EDA, edaravone (0.1 mM); CIP+E: ciprofloxacin (0.002 mg/liter) plus edaravone (0.1 mM); LEV, levofloxacin (0.016 mg/liter); TMP, trimethoprim (0.03 mg/liter); FOS, fosfomycin (2 mg/liter); AMX, amoxicillin (512 mg/liter); AMC, amoxicillin-clavulanic acid (2/4 mg/liter); NIT, nitrofurantoin (2 mg/liter); CFX, cephalexin (256 mg/liter); ERY, erythromycin (16 mg/liter). Fold change in mRNA levels were determined by RT-qPCR. The data were normalized to the 16S rRNA gene. Three independent replicates were performed. Bold indicates significant results (P < 0.05).